Cardiovascular Drug Discovery: A Perspective from a Research-Based Pharmaceutical Company | Zendy

Gianni Gromo | Zendy; Jessica Mann | Zendy; John D. FitzGerald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular Drug Discovery: A Perspective from a Research-Based Pharmaceutical Company

Author(s) -

Gianni Gromo,

Jessica Mann,

John D. FitzGerald

Publication year - 2014

Publication title -

cold spring harbor perspectives in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.853

H-Index - 105

eISSN - 2472-5412

pISSN - 2157-1422

DOI - 10.1101/cshperspect.a014092

Subject(s) - pharmaceutical industry , engineering ethics , drug discovery , perspective (graphical) , theme (computing) , pharmaceutical sciences , face (sociological concept) , medicine , business , pharmacology , computer science , sociology , bioinformatics , engineering , biology , social science , artificial intelligence , operating system

The theme of this review is to summarize the evolving processes in cardiovascular drug discovery and development within a large pharmaceutical company. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the effectiveness of research collaboration between the two constituencies, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized. The need for improved therapy in many cardiovascular indications remains high, but the feasibility in making progress, despite the advances in molecular biology and genomics, is also assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research